On The Readout LOUD this week, STAT reporters discuss the FDA's staff cuts, how next-gen drugs may lead to too much weight ...
From the intensifying battle over weight-loss drugs to the rise of AI to the uncertainty about President-elect Donald Trump's second term, biotech stocks won't be boring in 2025. Biotech may even ...